POWEL H BROWN to Breast Neoplasms
This is a "connection" page, showing publications POWEL H BROWN has written about Breast Neoplasms.
Connection Strength
1.779
-
Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest. 2015 Jul 01; 125(7):2707-20.
Score: 0.092
-
TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):E3216-25.
Score: 0.091
-
Prevention: targeted therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol. 2014 Mar; 11(3):127-8.
Score: 0.084
-
Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila). 2011 Aug; 4(8):1149-57.
Score: 0.070
-
Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.
Score: 0.062
-
A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin. Cancer Prev Res (Phila). 2009 Nov; 2(11):915-8.
Score: 0.062
-
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40.
Score: 0.062
-
Prevention of ER-negative breast cancer. Recent Results Cancer Res. 2009; 181:121-34.
Score: 0.059
-
Breast cancer prevention using calcium and vitamin D: a bright future? J Natl Cancer Inst. 2008 Nov 19; 100(22):1562-4.
Score: 0.058
-
Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55.
Score: 0.056
-
The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2008 Jan 10; 27(3):366-77.
Score: 0.053
-
Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev. 2007 Jun; 16(3):203-15.
Score: 0.052
-
Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs. 2006 Dec; 15(12):1583-600.
Score: 0.051
-
Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer. 2005 Apr; 6(1):27-37.
Score: 0.045
-
Risk assessment: controversies and management of moderate- to high-risk individuals. Breast J. 2005 Mar-Apr; 11 Suppl 1:S11-9.
Score: 0.045
-
Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3.
Score: 0.044
-
AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene. 2004 Oct 28; 23(50):8238-46.
Score: 0.044
-
Should tamoxifen be used in breast cancer prevention? Drug Saf. 2004; 27(13):979-89.
Score: 0.041
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.041
-
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31.
Score: 0.040
-
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst. 2003 Jun 04; 95(11):766-7.
Score: 0.040
-
Prevention of breast cancer--present reality and future promise. J Mammary Gland Biol Neoplasia. 2003 Jan; 8(1):1-3.
Score: 0.039
-
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
Score: 0.038
-
Chemoprevention of breast cancer. Breast Cancer Res Treat. 2000 Jul; 62(1):1-17.
Score: 0.032
-
Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst. 1999 Nov 03; 91(21):1809-19.
Score: 0.031
-
Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia. 1999 Oct; 4(4):377-88.
Score: 0.031
-
Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997 Jul 15; 57(14):3046-54.
Score: 0.026
-
Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar; 15(3):215-26.
Score: 0.024
-
AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.
Score: 0.022
-
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10; 31(23):2942-62.
Score: 0.020
-
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54.
Score: 0.019
-
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
Score: 0.017
-
Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503.
Score: 0.017
-
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
Score: 0.017
-
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
Score: 0.016
-
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 01; 27(19):3235-58.
Score: 0.015
-
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
Score: 0.015
-
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
Score: 0.015
-
Chemoprevention clinical trials: it is time to turn success into progress. Cancer Epidemiol Biomarkers Prev. 2007 Aug; 16(8):1531-2.
Score: 0.013
-
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76.
Score: 0.013
-
Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18.
Score: 0.013
-
Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 2006 May 15; 66(10):5304-13.
Score: 0.012
-
Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat. 2006 Sep; 99(2):121-34.
Score: 0.012
-
Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 2006 Dec 08; 244(2):203-10.
Score: 0.012
-
Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat. 2006 Mar; 96(2):147-57.
Score: 0.012
-
cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24.
Score: 0.012
-
Cancer prevention: the importance of accurate risk assessment. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1357-8.
Score: 0.011
-
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6(6):240-5.
Score: 0.011
-
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
Score: 0.009
-
Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog. 2002 Apr; 33(4):228-36.
Score: 0.009
-
AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80.
Score: 0.009
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.008
-
cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.
Score: 0.008
-
RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog. 1998 Aug; 22(4):247-57.
Score: 0.007
-
Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res. 1997 Oct 15; 57(20):4652-61.
Score: 0.007
-
Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog. 1997 Jul; 19(3):180-90.
Score: 0.007
-
A SNP in steroid receptor coactivator-1 disrupts a GSK3? phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol. 2012 Feb; 26(2):220-7.
Score: 0.004
-
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009 May; 10(5):501-7.
Score: 0.004
-
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem. 2001 Jul 27; 276(30):27907-12.
Score: 0.002